Phase
Condition
Liver Disorders
Hepatitis
Treatment
Use of Tappt App
Clinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
18 years of age or older
Hepatitis C virus (HCV) infection (denoted by positive HCV antibody and detectableHCV RNA)
Initiating oral HCV therapy with glecaprevir/pibrentasvir or sofosbuvir/velpatasvir
HCV treatment provided and managed by the clinical pharmacist at UI Health
Access to a mobile smartphone (iPhone 7 or later; Android release date 2012 orlater) with reliable data and/or Wi-Fi access
Ability to verbalize understanding of the study protocol in English
Able and willing to provide informed consent in English
Exclusion
Exclusion Criteria:
Inability to speak and read English
Inability or unwillingness to adhere to the study protocol
Pregnant individuals
Decompensated cirrhosis (Child Turcotte Pugh Class B and C); hepatocellularcarcinoma; prior liver or kidney transplant
No patient will be excluded because of gender, race or ethnic origin.
The following populations will be excluded from the study:
Adults 18 years of age and older who are unable or unwilling to consent
Individuals less than 18 years old
Pregnant individuals
Prisoners
Study Design
Connect with a study center
UIH
Chicago, Illinois 60612
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.